{"title":"儿童和青少年急性白血病患者的感染问题","authors":"Fabianne Carlesse , Ana Virginia Lopes de Sousa","doi":"10.1016/j.ejcped.2024.100142","DOIUrl":null,"url":null,"abstract":"<div><p>The incidence and spectrum of infections in pediatric leukemia patients vary depending on the type of leukemia. AML, which involves intensive chemotherapeutic regimes, leads to profound and prolonged neutropenia, making children more susceptible to infection. The intensity of chemotherapy, the duration of neutropenia, and antimicrobial prophylaxis implementation all affect the risk of life-threatening infections. In AML studies have shown that during intensive treatment, children experience more than one episode of infection, with majority being bacteremias. Viridans group <em>Streptococci</em> comprises around 20% of all isolates. Infection related deaths range from 5.4% to 7.3% during chemotherapy being more frequent on intensive phase. Invasive fungal infections (IFI) were highly associated with mortality specially caused by <em>Aspergillus</em> spp. In ALL induction and consolidation phases posing a higher risk for infections due to severe neutropenia. Infection related mortality in ALL is 2–4%, and infections are the main cause of treatment related deaths. IFI are significant concern with risk factors including age and treatment intensity. High risk include older children, delayed response during early induction therapy and corticosteroid administration. In summary, while survival rates for childhood leukemia have improved, the risk of infections, particularly bacterial and fungal infections, remains a significant concern, especially during intensive treatment phases. Ongoing research is needed to better understand and manage these infections in pediatric leukemia patients</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100142"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000011/pdfft?md5=dfd47e6a4db77a35cfcc6e8cdb9af4da&pid=1-s2.0-S2772610X24000011-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Infections in children and adolescents with Acute Leukemia\",\"authors\":\"Fabianne Carlesse , Ana Virginia Lopes de Sousa\",\"doi\":\"10.1016/j.ejcped.2024.100142\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The incidence and spectrum of infections in pediatric leukemia patients vary depending on the type of leukemia. AML, which involves intensive chemotherapeutic regimes, leads to profound and prolonged neutropenia, making children more susceptible to infection. The intensity of chemotherapy, the duration of neutropenia, and antimicrobial prophylaxis implementation all affect the risk of life-threatening infections. In AML studies have shown that during intensive treatment, children experience more than one episode of infection, with majority being bacteremias. Viridans group <em>Streptococci</em> comprises around 20% of all isolates. Infection related deaths range from 5.4% to 7.3% during chemotherapy being more frequent on intensive phase. Invasive fungal infections (IFI) were highly associated with mortality specially caused by <em>Aspergillus</em> spp. In ALL induction and consolidation phases posing a higher risk for infections due to severe neutropenia. Infection related mortality in ALL is 2–4%, and infections are the main cause of treatment related deaths. IFI are significant concern with risk factors including age and treatment intensity. High risk include older children, delayed response during early induction therapy and corticosteroid administration. In summary, while survival rates for childhood leukemia have improved, the risk of infections, particularly bacterial and fungal infections, remains a significant concern, especially during intensive treatment phases. Ongoing research is needed to better understand and manage these infections in pediatric leukemia patients</p></div>\",\"PeriodicalId\":94314,\"journal\":{\"name\":\"EJC paediatric oncology\",\"volume\":\"3 \",\"pages\":\"Article 100142\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772610X24000011/pdfft?md5=dfd47e6a4db77a35cfcc6e8cdb9af4da&pid=1-s2.0-S2772610X24000011-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJC paediatric oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772610X24000011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJC paediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772610X24000011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
小儿白血病患者感染的发生率和范围因白血病类型而异。急性髓细胞性白血病(AML)涉及强化化疗方案,会导致严重和长期的中性粒细胞减少,使患儿更容易受到感染。化疗的强度、中性粒细胞减少的持续时间以及抗菌药预防措施的实施都会影响危及生命的感染风险。对急性髓细胞白血病的研究表明,在强化治疗期间,患儿会经历一次以上的感染,其中大多数是菌血症。病毒性链球菌约占所有分离菌株的 20%。化疗期间与感染相关的死亡率为 5.4% 至 7.3%,在强化治疗阶段更为常见。侵袭性真菌感染(IFI)与死亡率高度相关,尤其是由曲霉菌属引起的感染。 在 ALL 诱导和巩固阶段,由于严重的中性粒细胞减少症,感染的风险更高。ALL 感染相关死亡率为 2-4%,感染是治疗相关死亡的主要原因。感染性骨髓纤维化是一个值得关注的问题,其风险因素包括年龄和治疗强度。高危因素包括年龄较大的患儿、早期诱导治疗反应延迟以及皮质类固醇用药。总之,虽然儿童白血病的存活率有所提高,但感染的风险,尤其是细菌和真菌感染,仍然是一个重大问题,特别是在强化治疗阶段。为了更好地了解和控制儿童白血病患者的感染,我们需要不断进行研究。
Infections in children and adolescents with Acute Leukemia
The incidence and spectrum of infections in pediatric leukemia patients vary depending on the type of leukemia. AML, which involves intensive chemotherapeutic regimes, leads to profound and prolonged neutropenia, making children more susceptible to infection. The intensity of chemotherapy, the duration of neutropenia, and antimicrobial prophylaxis implementation all affect the risk of life-threatening infections. In AML studies have shown that during intensive treatment, children experience more than one episode of infection, with majority being bacteremias. Viridans group Streptococci comprises around 20% of all isolates. Infection related deaths range from 5.4% to 7.3% during chemotherapy being more frequent on intensive phase. Invasive fungal infections (IFI) were highly associated with mortality specially caused by Aspergillus spp. In ALL induction and consolidation phases posing a higher risk for infections due to severe neutropenia. Infection related mortality in ALL is 2–4%, and infections are the main cause of treatment related deaths. IFI are significant concern with risk factors including age and treatment intensity. High risk include older children, delayed response during early induction therapy and corticosteroid administration. In summary, while survival rates for childhood leukemia have improved, the risk of infections, particularly bacterial and fungal infections, remains a significant concern, especially during intensive treatment phases. Ongoing research is needed to better understand and manage these infections in pediatric leukemia patients